Eton Pharmaceuticals (ETON) to Release Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Eton Pharmaceuticals to post earnings of ($0.02) per share and revenue of $10.53 million for the quarter.

Eton Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ ETON opened at $15.17 on Thursday. The firm’s 50-day moving average price is $15.12 and its 200-day moving average price is $10.70. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $18.41. The company has a market cap of $395.19 million, a PE ratio of -68.95 and a beta of 1.37.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ETON. B. Riley began coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.